Human Pluripotent Stem Cell Staging for Monohormonal Beta Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to generate enriched populations of mono-hormonal pancreatic beta cells, particularly those producing exclusively insulin, from human pluripotent stem cells, which are crucial for diabetes treatment.
Innovation Solution
A method involving sequential exposure of pluripotent stem cells to specific growth factors and small molecules, such as CHIR99021, Activin A, FGF7, retinoic acid, LDN193189, and SANT1, followed by differentiation in basal medium, generates enriched populations of monohormonal pancreatic beta cells (PP2-β cells) that express insulin but not glucagon or ghrelin, and are characterized by high expression of markers like NKX6.1 and NEUROD1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation methods are used, then pancreatic beta cells can be generated, but the population is not enriched for mono-hormonal cells and contains multiple hormone types
Solution Approach 1:
The differentiation process is divided into distinct sequential stages: definitive endoderm formation, pancreatic progenitor specification, and beta cell maturation. Each stage uses specific growth factors and small molecules to guide cells through precise developmental transitions, enabling enrichment of mono-hormonal beta cells while maintaining overall differentiation efficiency
Solution Approach 2:
The method applies preliminary actions by pre-treating pluripotent stem cells with specific combinations of growth factors (Activin A, FGF7) and small molecules (CHIR99021, retinoic acid, LDN193189, SANT1) at each differentiation stage to pre-commit cells toward the beta cell lineage before final differentiation, ensuring high purity of mono-hormonal cells
2Manufacturing precision
If sequential exposure to multiple growth factors and small molecules is applied, then enriched mono-hormonal beta cell populations are generated, but the protocol complexity increases
Solution Approach 1:
The complex differentiation protocol is segmented into discrete stages, each with a defined combination of growth factors and small molecules. This segmentation allows systematic control of cell fate decisions while maintaining reproducibility and reducing overall protocol complexity through modular design
Solution Approach 2:
The method systematically changes chemical parameters (growth factor concentrations, small molecule additions/removals) at each differentiation stage to guide cells through specific developmental transitions. These parameter changes are precisely timed and controlled to achieve mono-hormonal enrichment without requiring overly complex protocol structures
Data Source
AI summary
Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.